Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
-
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
Mots clés
Beta-catenin
Systemic therapy
Radiofrequency ablation
Androgen insensitivity
Circulating tumor DNA
Invasive cutaneous squamous cell carcinoma
Anti-CTLA-4
TNM classification
Wnt
Bisphosphonates
Immune checkpoint inhibitor
Anti-Tumor pharmacology
Adjuvant
ALK rearrangement
Bone lesion
Prognosis
Body mass index
Sonic Hedgehog
Merkel cell carcinoma
Resistance
Cutaneous squamous cell carcinoma
Immunotherapy
Adverse events
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Biomarker
Gastric bypass
Osimertinib
Nivolumab
Children
Cemiplimab
BRAFV600-mutant melanoma
Melanoma
Mesenchymal stromal cells
Assisted reproductive techniques
BRAF V600E
Chemotherapy
BRAFV600E mutation
Molecular targeted therapies
Advanced melanoma
Biomarkers
Metastatic cSCC
Langerhans cell histiocytosis
ADN tumoral circulant
Acute generalized exanthematous pustulosis
Liver metastases
Colon cancer
Prevention
ALK
EGFR
Chemoresistance
Diagnosis
Metastatic
Adjuvant therapy
Adjuvant FOLFOX
Staging
Bariatric surgery
Antineoplastic agents
Follow-up
Anti-PD1 blockade
Anti-PD-1 antibody
Polyomavirus
AZD9291
Safety
Crizotinib
Locally advanced
Anti-PD-1
Survival
BRAF
Prognostic
ACTH
Advanced
Surgical excision
Histiocytosis
BRAF V600-mutation
Trametinib
Plasma
Dabrafenib
Targeted therapy
Circulating cell-free DNA
BRAFV600E
Anti-PD1
Abdominal pain
2-chlorodeoxyadenosine
Non-small cell lung cancer
AML
Biliopancreatic diversion
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Immunohistochemistry
Antibody-drug conjugate
Abscopal effect
Cancer bronchique non à petites cellules
Allelic imbalance
Cancer
Immunomodulation
Colorectal carcinoma
Lung adenocarcinoma
Treatment
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Radiotherapy
Colorectal cancer